Public Health and the Environment | Geneva 2009
Lancet 2017; 390: 2437–60
Lancet Public Health 2019; 4: e89–96Published OnlineNovember 13, 2018 http://dx.doi.org/10.1016/ S2468-2667(18)30203-2
In the spirit of the Sustainable Development Goals, WHO and the International Labour Organization (ILO) produce the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury (WHO/ILO Joint Estimates). The WHO/ILO Joint Estimates quantify the population exposed to occupational risk fac...tors and amount health loss caused by these exposures. Global, regional and national estimates are produced of the numbers of deaths and disability-adjusted life years that can be attributed to exposure to selected occupational risk factors. Estimates are produced disaggregated by sex and age group.
more
This booklet provides an overview of all findings from the Global Burden of Disease 2017 study. Published in The Lancet in November 2018, GBD 2017 provides for the first time an independent estimation of population, for each of 195 countries and territories and the globe, using a standardized, repli...cable approach, as well as a comprehensive update on fertility. Produced with the input of 3,676 collaborators from 146 countries and territories, GBD 2017 incorporates major data additions and improvements, and methodological refinements. GBD 2017 also includes estimates at the subnational level for selected locations.
more
Public Health and the Environment
Lancet Neurol. Volume 18, ISSUE 5, P439-458, May 01, 2019
Published Mar 11. pii: S1474-4422(19)30034-1. doi: 10.1016/S1474-4422(19)30034-1.
Lancet Neurol 2019 Volume 18, ISSUE 5, P459-480, May 01, 2019
Published OnlineMarch 14, 2019 http://dx.doi.org/10.1016/ S1474-4422(18)30499-X
Lancet Neurol. 2019 Apr;18(4):357-375. doi: 10.1016/S1474-4422(18)30454-X. Epub 2019 Feb 14.
Lancet Glob Health 2018, Published Online September 12, 2018 http://dx.doi.org/10.1016/S2214-109X(18)30387-5
Lancet Public Health 2018 Published Online September 12, 2018 http://dx.doi.org/10.1016/ S2468-2667(18)30138-5
Lancet Public Health. 2019 Dec 20. pii: S2468-2667(19)30246-4. doi: 10.1016/S2468-2667(19)30246-4.
The Lancet. 1 December 2020. doi: 10.1016/S0140-6736(20)32340-0.
To our knowledge, this is the first study to produce a global estimate of the need for rehabilitation services and to show that at least one in every three people in the world needs rehabilitation at some point in the course of their ...illness or injury. This number counters the common view of rehabilitation as a service required by only few people. We argue that rehabilitation needs to be brought close to communities as an integral part of primary health care to reach more people in need.
more
The Lancet Published Online
October 8, 2021 https://doi.org/10.1016/ S0140-6736(21)02143-7
Lancet Public health 2022 January 6, 2022 https://doi.org/10.1016/ S2468-2667(21)00249-8
Growth in the number of individuals living with dementia underscores the need for public health planning efforts and policy to address the needs of this group. Country-level estimates can be used to inform nati...onal planning efforts and decisions. Multifaceted approaches, including scaling up interventions to address modifiable risk factors and investing in research on biological mechanisms, will be key in addressing the expected increases in the number of individuals affected by dementia.
more
Lancet Infect Dis 2022;
22: 222–4
The main message emerging from this new comprehensive global assessment is that premature death and disease can be prevented through healthier environments – and to a significant degree. Analysing the latest data on the environment-disease nexus and the devastating impact of environmental hazards ...and risks on global health, backed up by expert opinion, this report covers more than 100 diseases and injuries.
more
Chagas disease (CD) is a neglected tropical disease, endemic in Latin America, but due to migration and environmental changes it has become a global public health issue.
Neglected tropical diseases (NTDs) are targeted for global control or elimination. Recognising that the populations most in need of medicines to target NTDs are those least able to support and sustain them financially, the pharmaceutical industry created mechanisms for donating medicines and experti...se to affected countries through partnerships with the WHO, development agencies, non-governmental organisations and philanthropic donors. In the last 30 y, companies have established programmes to donate 17 different medicines to overcome the burden of NTDs. Billions of tablets, capsules, intravenous and oral solutions have been donated, along with the manufacturing, supply chains and research necessary to support these efforts. Industry engagement has stimulated other donors to support NTDs with funds and oversight so that the ‘heath benefit’ return on investment in these programmes is truly a ‘best value in public health’. Many current donations are ‘open-ended’, promising support as long as necessary to achieve defined health targets. Extraordinary global health advances have been made in filariasis, onchocerciasis, trachoma, trypanosomiasis, leishmaniasis, schistosomiasis, intestinal parasites and others; and these advances are taking place in the context of strengthening health systems and meeting the global development goals espoused by the WHO. The pharmaceutical manufacturers, already strong collaborators in initiating or supporting these disease-targeted programmes, have committed to continuing their partnership roles in striving to meet the targets of the WHO’s new NTD roadmap to 2030.
more